<qa>  What is the potential for hyperviscosity syndrome?10.1 This includes Waldenstroms Macroglobulinemia, since such patients have experienced transient increases in IgM following initiation of rituximab, with the potential for hyperviscosity syndrome requiring plasmapheresis. 